-+ 0.00%
-+ 0.00%
-+ 0.00%

Jianfeng Group announced that Jianfeng Pharmaceutical, a wholly-owned subsidiary of the company, and its subsidiaries added 4 new products to the “National Essential Drug Catalogue”, including tafluprost eye drops, roxastat capsules, etc. The total sales revenue of the above drugs in 2025 was about 3.1 million yuan, accounting for about 0.12% of the company's 2025 revenue. The selection of this product will have a positive effect on market expansion and will not have a significant impact on business performance in the short term.

Zhitongcaijing·07/10/2026 07:41:06
Listen to the news
Jianfeng Group announced that Jianfeng Pharmaceutical, a wholly-owned subsidiary of the company, and its subsidiaries added 4 new products to the “National Essential Drug Catalogue”, including tafluprost eye drops, roxastat capsules, etc. The total sales revenue of the above drugs in 2025 was about 3.1 million yuan, accounting for about 0.12% of the company's 2025 revenue. The selection of this product will have a positive effect on market expansion and will not have a significant impact on business performance in the short term.